Wydanie specjalne czerwiec 2014
Aflibercept w leczeniu neowaskularnej postaci zwyrodnienia plamki związanego z wiekiem – pierwsze doświadczenia kliniczne
Aflibercept in the Treatment of Neovascular Age-related Macular Degeneration – First Clinical Experience
Elżbieta Oczkowska, Alicja Dębicka
Niepubliczny Specjalistyczny Zakład Opieki Zdrowotnej Centrum Medyczne VISUS w Starachowicach
Kierownik: dr n. med. Alicja Dębicka
Summary: Purpose: The aim of the study is to present and discuss four cases of neovascular age-related macular degeneration treated with aflibercept.
Material and Methods: All four patients came to Medical Center Visus due to vision loss. Basic ophthalmic examination and additional diagnostic methods including fluorescein angiography and optical coherence tomography were performed. They confirm diagnosis of neovascular age related macular degeneration in one eye et least. The first case was treated with three aflibercept injections every month. In the second case one ranibizumab and three aflibercept injections every month were given. In the third case at the beginning two bevacizumab injections and one aflibercept year later were given. Fourth case was treated with multiple injections on elastic scheme: three bevacizumab, four ranibizumab, three aflibercept and one ranibizumab at the end.
Results: In first three cases there was a very good response to aflibercept treatment. In second and third case better effectiveness of this drug was observed comparing other medications. Only in first case visual aquity increased, in another two only anatomic effect was observed. In fourth case there was no positive response after treatment, only retinal condition stabilization.
Discussion: Treatment results which were observed depend on using drug specification, disease progression at the treatment beginning and elastic therapeutic scheme. Such method of treatment is not recommended in the literature, but depends on economical situation. Continous aflibercept injections every two months give not only economic adventages, but first of all increase safety of intravitreal therapy.
Conclusions: Case reports of treating patients and results of clinical research indicate, that aflibercept is currently the most recommended medication in neovascular age-related macular degeneration treatment.
Słowa kluczowe: aflibercept, neowaskularna postać zwyrodnienia plamki związanego z wiekiem (AMD), terapia antyangiogenna, optyczna koherentna tomografia (OCT).
Keywords: aflibercept, neovascular age-related macular degeneration (AMD), anti-angiogenic therapy, optical coherence tomography (OCT).